Work

140P Tislelizumab combined with lenvatinib and transarterial chemoembolization(TACE) neoadjuvant treatment in resectable CNLC IIa-IIb hepatocellular carcinoma: A prospective, single-arm, phase II study

Year: 2024

Type: article

Abstract: Background: Until recently, neoadjuvant therapy for HCC has been limited by a lack of effective approaches.Prior studies have shown that patients (pts) achieving major pathological response (MPR) with neoadjuvant therapy have improved recurrencefree survival (RFS) in early-stage hepatocellular carcinoma (HCC).This prospective study aimed to explore the efficacy and safety of TACE combined with lenvatinib and tislelizumab in high-risk resectable HCC pts.

Source: Immuno-Oncology Technology

DOI: 10.1016/j.iotech.2024.100769